Botanix Releases Quarterly Reports

/in , , , /by

Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.

Botanix Featured in AFR

/in , /by

The Australian Financial Review has featured Botanix as an ASX favourite.

In an article profiling stock picks by Liam Donohue from Lennox Capital, he assessed the market opportunity for Sofdra™:

‘…current treatments have been more invasive (such as targeted Botox injections) and typically less effective.

‘So, with many of the more binary risks out of the way for Botanix, we think the opportunity in front of the company is immense. That is especially the case when you couple this with management’s history of commercialising pharma products in the US.’

Click here to read the full article.

The West Australian: ‘Botanix ships first batch of sweat-stopper gel’

/in , , /by

Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.

Read article

First Sofdra™ prescriptions as commercialization ramps up

/in , , , /by

First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.

View release.

Botanix presentation at Bell Potter Healthcare Conference

/in , , , /by

Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.

View ASX release.

Botanix adds Payer coverage representing ~65 million commercial lives

/in , , , /by

Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.

View release.

Botanix Releases Quarterly Reports

/in , , , /by

Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.

View Report.

From The Helm | Interview with CEO Dr Howie McKibbon

/in , , , /by

While in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months. 

Take a look: 

Ausbiz | Interview with Howie McKibbon

/in , , , /by

Botanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.

During his visit, he was interviewed in the Ausbiz studio to discuss the Company’s comprehensive commercialisation plans for Sofdra™. Take a look: